Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib, Methylprednisolone and Lenalidomide in RRMM Using BCMA
NCT06209606Phase 1Recruiting
- Sponsor
- ONCOtherapeutics
- Start
- Dec 2022
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ruxolitinib in multiple myeloma (MM) (2 arms), sponsored by ONCOtherapeutics. Primary endpoint: Time to Disease Progression at 54 months. Started Dec 2022; status: recruiting.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06209606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06209606.